Search

Displaying results 4041 - 4050 of 10000 in total
  1. Drug

    Lumretuzumab

    go.drugbank.com/drugs/DB12683
    Investigational

    Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.

  2. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  3. Drug

    Benziodarone

    go.drugbank.com/drugs/DB13277
    ApprovedWithdrawn

    Benziodarone is a uricostatic and a uricosuric agent which is sold also under the name Amplivex-Labaz. It is used in the treatment of gout [A175630].

  4. Drug

    Nifuroxazide

    go.drugbank.com/drugs/DB13855
    Investigational

    Mixtures: METARSAL N CAPSULAS, DIARSET NX® M CAPSULAS
  5. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.

  6. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  7. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    The Company determined that the program was not meeting their expected primary and exploratory objectives. … It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  8. Drug

    Bromazepam

    go.drugbank.com/drugs/DB01558
    ApprovedIllicit

    One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.

    Products: BROMAZEPAM N&P
  9. Drug

    Fulzerasib

    go.drugbank.com/drugs/DB21609
    Investigational

    Fulzerasib has a monoisotopic molecular weight of 630.22 Da. … NCT06936644 (A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small

  10. Drug

    Pramiracetam

    go.drugbank.com/drugs/DB13247
    Approved

    Pramiracetam has been previously approved in some eastern European countries under the brand names Pramistar, Neupramir, and Remen.